Recent advances in nanomedicine for metabolism-targeted cancer therapy
Metabolism denotes the sum of biochemical reactions that maintain cellular function. Different from most normal differentiated cells, cancer cells adopt altered metabolic pathways to support malignant properties. Typically, almost all cancer cells need a large number of proteins, lipids, nucleotides, and energy in the form of ATP to support rapid division. Therefore, targeting tumour metabolism has been suggested as a generic and effective therapy strategy. With the rapid development of nanotechnology, nanomedicine promises to have a revolutionary impact on clinical cancer therapy due to many merits such as targeting, improved bioavailability, controllable drug release, and potentially personalized treatment compared to conventional drugs. This review comprehensively elucidates recent advances of nanomedicine in targeting important metabolites such as glucose, glutamine, lactate, cholesterol, and nucleotide for effective cancer therapy. Furthermore, the challenges and future development in this area are also discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Chemical communications (Cambridge, England) - 60(2024), 18 vom: 27. Feb., Seite 2442-2461 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Da, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.02.2024 Date Revised 28.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1039/d3cc05858a |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368111784 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368111784 | ||
| 003 | DE-627 | ||
| 005 | 20240229170902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1039/d3cc05858a |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM368111784 | ||
| 035 | |a (NLM)38321983 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Da, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent advances in nanomedicine for metabolism-targeted cancer therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Metabolism denotes the sum of biochemical reactions that maintain cellular function. Different from most normal differentiated cells, cancer cells adopt altered metabolic pathways to support malignant properties. Typically, almost all cancer cells need a large number of proteins, lipids, nucleotides, and energy in the form of ATP to support rapid division. Therefore, targeting tumour metabolism has been suggested as a generic and effective therapy strategy. With the rapid development of nanotechnology, nanomedicine promises to have a revolutionary impact on clinical cancer therapy due to many merits such as targeting, improved bioavailability, controllable drug release, and potentially personalized treatment compared to conventional drugs. This review comprehensively elucidates recent advances of nanomedicine in targeting important metabolites such as glucose, glutamine, lactate, cholesterol, and nucleotide for effective cancer therapy. Furthermore, the challenges and future development in this area are also discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 700 | 1 | |a Di, XinJia |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, YuQi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, JiLi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, LiLi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, YanLan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical communications (Cambridge, England) |d 1998 |g 60(2024), 18 vom: 27. Feb., Seite 2442-2461 |w (DE-627)NLM095512322 |x 1364-548X |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2024 |g number:18 |g day:27 |g month:02 |g pages:2442-2461 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1039/d3cc05858a |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2024 |e 18 |b 27 |c 02 |h 2442-2461 | ||